The Neurovascular Unit Dysfunction in Alzheimer's Disease

Alzheimer's disease (AD) is the most common neurodegenerative disease worldwide. Histopathologically, AD presents with two hallmarks: neurofibrillary tangles (NFTs), and aggregates of amyloid beta peptide (A beta) both in the brain parenchyma as neuritic plaques, and around blood vessels as cerebral amyloid angiopathy (CAA). According to the vascular hypothesis of AD, vascular risk factors can result in dysregulation of the neurovascular unit (NVU) and hypoxia. Hypoxia may reduce A beta clearance from the brain and increase its production, leading to both parenchymal and vascular accumulation of A beta. An increase in A beta amplifies neuronal dysfunction, NFT formation, and accelerates neurodegeneration, resulting in dementia. In recent decades, therapeutic approaches have attempted to decrease the levels of abnormal A beta or tau levels in the AD brain. However, several of these approaches have either been associated with an inappropriate immune response triggering inflammation, or have failed to improve cognition. Here, we review the pathogenesis and potential therapeutic targets associated with dysfunction of the NVU in AD.

Automated summary

Alzheimer's disease is the most common neurodegenerative disease worldwide, characterized by neurofibrillary tangles and amyloid beta accumulation. Vascular risk factors may lead to dysregulation of the neurovascular unit, contributing to A beta accumulation and neurodegeneration. Therapeutic approaches targeting abnormal A beta levels have had limited success in improving cognition.